Fig 1: CHROMR, miR-1299, and CNNM1 expression in different resistant cell lines and verification of their targets. (A) Predictive targets of CHROMR and miR-1299, miR-1299, and CNNM1. (B) The expression of miR-1299 in different cell lines of DLBCL was detected by RT-qPCR. (C) The expression of CNNM1 in different cell lines of DLBCL was detected by RT-qPCR. (D) The expression of CHROMR in different cell lines of DLBCL was detected by RT-qPCR. (E) Verification of the target of CHROMR and miR-1299 by dual luciferase experiment. (F) Verification of the target of CNNM1 and miR-1299 by dual luciferase experiment. *, P<0.05; ***, P<0.001. DLBCL, diffuse large B-cell lymphoma; WT, wild type; NC, negative control; MUT, mutant type; RT-qPCR, real time quantitative polymerase chain reaction.
Fig 2: Verification of the CHROMR/miR-1299/CNNM1 pathway through cell function, RT-qPCR, and Western Blot experiments. (A) After transfection of CHROMR-over plasmid and miR-1299 mimic recovery, we detected CHROMR, miR-1299, CNNM1 expression changes in SU_DHL_4 cell line by RT-qPCR. (B) After transfection of CHROMR-over plasmid and miR-1299 mimic recovery, we detected apoptosis-related genes and CNNM1 expression by Western Blot. + indicates that the substance is transfected, − indicates that the substance is not transfected. (C) In the case of rituximab killing, flow cytometry detected the proportion of cells in the G2 phase of each group. (D) In the case of rituximab killing, the proportion of apoptosis in each group was detected by flow cytometry. ***, P<0.001. NC, negative control; RT-qPCR, real time quantitative polymerase chain reaction.
Fig 3: CHROMR’s role in the DLBCL cell line. (A) After CHROMR overexpression, detect CHROMR, miR-1299, and CNNM1 expression changed in SU_DHL_4 cell line by RT-qPCR. (B) After CHROMR overexpression, we detected apoptosis-related genes and CNNM1 expression by Western Blot. (C) In the case of rituximab killing, flow cytometry detected the proportion of cells in the G2 phase of each group. (D) In the case of rituximab killing, the proportion of apoptosis in each group was detected by flow cytometry. (E) After CHROMER overexpression, we detected cell proliferation ability of each group by cck8. *, P<0.05; ***, P<0.001. NC, negative control; DLBCL, diffuse large B-cell lymphoma; RT-qPCR, real time quantitative polymerase chain reaction.
Supplier Page from Abcam for Anti-CNNM1 antibody